BiotechTube

Ixekizumab + Placebo + Adalimumab

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing

Trial Timeline

Jul 1, 2014 → Apr 1, 2018

NCT ID
NCT01870284

About Ixekizumab + Placebo + Adalimumab

Ixekizumab + Placebo + Adalimumab is a phase 3 stage product being developed by Eli Lilly for Spondylitis, Ankylosing. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01870284. Target conditions include Spondylitis, Ankylosing.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT02696785Phase 3Completed
NCT01870284Phase 3Withdrawn
NCT01695239Phase 3Completed

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
placebo for risankizumab + risankizumabAbbViePhase 2
52
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85
InfliximabMerckApproved
85

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85